[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 7,116
Citations 0
Medical News & Perspectives
November 24, 2015

Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies

JAMA. 2015;314(20):2117-2119. doi:10.1001/jama.2015.10795

The origins of cancer immunotherapy date back more than 2 decades to when researchers explored ways to amplify the immune system to attack tumor cells. At the time, scientists hypothesized that tumors were able to evade immune surveillance because tumor cells lacked costimulatory molecules required to signal T cells to the presence of the tumor.

However, in the mid-1990s, James P. Allison, PhD, and his colleagues at the University of California, Berkeley, Cancer Research Laboratory discovered that rather than lack costimulatory molecules, tumor cells and other immune cells expressed inhibitory molecules that disabled T cells from recognizing and eliminating tumors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×